 Home > Active Ingredient News > Study of Nervous System > Neurology: University of Cambridge: Dementia with Lewy bodies, clinical progress can be quantitatively tracked

Neurology: University of Cambridge: Dementia with Lewy bodies, clinical progress can be quantitatively tracked

 Last Update: 2021-09-10
 Source: Internet
 Author: User

Tags

fmld disease

cholesterol synthesized body

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Lewy body dementia (Dementia with Lewy bodies, DLB) and Parkinson's disease dementia (Parkinson's disease dementia, PDD) are collectively referred to as Lewy body dementia (Lewy body dementia), which is characterized by dementia with common clinical features, including exercise-induced dementia.
Kinsen disease; recurring visual hallucinations; cognitive fluctuations; and REM sleep behavior disorder
.

Despite the significant impact on public health, the main challenges in this area have resulted in relatively few disease-modifying trials for DLB and PDD
.

The main challenge is: how to determine appropriate clinical outcome measurements (outcome measurements) to track the development and severity of the disease
.

How to determine appropriate clinical outcome measurements (outcome measurements) to track the development and severity of the disease
.

At present, there are few prospective studies that directly explore the main clinical features of Lewy body dementia
.

Existing research focuses on changes in cognitive outcomes, while the natural history of neuropsychiatric characteristics, motor Parkinson's disease, fluctuations, and sleep symptoms is poorly understood, especially in the typical 6-month period in clinical trials Within the frame

In order to solve this problem, Elie Matar and others of the University of Cambridge used commonly used clinical scoring scales to analyze the main clinical features and symptom areas (cognitive impairment, motor Parkinson’s disease, recognition of PDD and DLB patients) within 6 months.

Quantify the trajectory and amplitude of changes in cognitive fluctuations, neuropsychiatric, and sleep disorders

They found that the cognitive ability of MMSE was significantly decreased by 1.

No obvious changes in neuropsychiatric symptoms were found
.

There is no difference in the rate of change of scores between DLB and PDD

No obvious changes in neuropsychiatric symptoms were found

Original source:
Matar E, White SR, Taylor JP, et al.

Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months.

Matar E, White SR, Taylor JP, et al.
Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months.
Neurology.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.